Protara Therapeutics, Inc. (TARA)
2025-06-30 | ||||
|---|---|---|---|---|
| Net unrealized gain (loss) on marketable debt securities | -12 | |||
| Other comprehensive income (loss) | -12 | |||
| Research and development | 10,770 | |||
| General and administrative | 5,816 | |||
| Total operating expenses | 16,586 | |||
| Income (loss) from operations | -16,586 | |||
| Other income (expense) | - | |||
| Interest and investment income (expense) | 1,626 | |||
| Other income (expense), net | 1,626 | |||
| Net income (loss) | -14,960 | |||
| Comprehensive income (loss) | -14,972 | |||
| Net income (loss) per share attributable to common stockholders, basic (in dollars per share) | -0.35 | |||
| Net income (loss) per share attributable to common stockholders, diluted (in dollars per share) | -0.35 | |||
| Weighted-average shares outstanding, basic (in shares) | 42,270,855 | |||
| Weighted-average shares outstanding, diluted (in shares) | 42,270,855 | |||